Previous 10 | Next 10 |
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs Sidney A. Spector, MD, PhD, appointed Senior VP, Global Strategy and Medical Affairs Kim Thacker, MD, appointed Senior VP, Medical Affairs and Clinical Innovation Sta...
Brainstorm Cell Therapeutics Announces Appointment of Menghis Bairu, MD, to Board of Directors PR Newswire NEW YORK , Oct. 28, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative d...
BrainStorm to Announce Third Quarter Financial Results and Provide a Corporate Update PR Newswire NEW YORK , Oct. 25, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, ...
BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at NYSCF 2021 VIRTUAL Meeting Superior clinical and biomarker outcomes demonstrated with NurOwn exosomes compared to MSC exosomes in preclinical ARDS models PR Newswire NEW Y...
Phase 2 Clinical Trial Data of NurOwn® in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) - Research Demonstrates Safety and Tolerability, Relevant CSF Biomarker Outcomes, and Prelimi...
BrainStorm to Present ALS Phase 3 Biomarker Analyses at Annual NEALS Meeting October 6th, 2021 PR Newswire NEW YORK , Oct. 6, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative di...
BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa PR Newswire NEW YORK , Oct. 4, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading develop...
Gainers: Ampio Pharmaceuticals (NYSE:AMPE) +22%, 180 Life Sciences (NASDAQ:ATNF) +17%, Brainstorm Cell Therapeutics (NASDAQ:BCLI) +15%, Instil Bio (NASDAQ:TIL) +16%, G Medical Innovations (NASDAQ:GMVD) +15%. Losers: Nuwellis (NASDAQ:NUWE) -26%...
BrainStorm Cell Therapeutics Inc. (BCLI) Q2 2021 Earnings Conference Call August 05, 2021, 08:00 AM ET Company Participants Chaim Lebovits - President and CEO Dr. Ralph Kern - President and CMO Dr. Preetam Shah - EVP and CFO Dr. Stacy Lindborg - EVP and Head of Global Clinical Research Dr. Da...
BrainStorm Cell Therapeutics (NASDAQ:BCLI): Q2 GAAP EPS of -$0.17 beats by $0.05. Cash, cash equivalents, and short-term bank deposits were ~$35M as of June 30, 2021, compared to ~$40.0Mon March 31, 2021. Press Release For further details see: BrainStorm Cell Therapeutics EPS beats by $...
News, Short Squeeze, Breakout and More Instantly...
Brainstorm Cell Therapeutics Inc. Company Name:
BCLI Stock Symbol:
NASDAQ Market:
Brainstorm Cell Therapeutics Inc. Website:
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program PR Newswire A conference call and webcast will be held Monday, July 8 , at 8:00 a.m. Eastern Time NEW YORK , July 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeut...
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering PR Newswire NEW YORK , June 27, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics fo...
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial PR Newswire NEW YORK , June 26, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell thera...